Stéphanie Guidez

1.8k total citations
45 papers, 387 citations indexed

About

Stéphanie Guidez is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Stéphanie Guidez has authored 45 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 22 papers in Hematology and 19 papers in Genetics. Recurrent topics in Stéphanie Guidez's work include Multiple Myeloma Research and Treatments (18 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Lymphoma Diagnosis and Treatment (16 papers). Stéphanie Guidez is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Lymphoma Diagnosis and Treatment (16 papers). Stéphanie Guidez collaborates with scholars based in France, United States and United Kingdom. Stéphanie Guidez's co-authors include Xavier Leleu, Charles Herbaux, Guillemette Fouquet, Thierry Façon, Cécile Tomowiak, Marie‐Hélène Delfau‐Larue, Malek Faham, Sarah Huet, Bettina Fabiani and Alain Delmer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Stéphanie Guidez

39 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stéphanie Guidez France 10 172 170 155 134 126 45 387
Τατιάνα Τζένου Greece 12 128 0.7× 200 1.2× 123 0.8× 145 1.1× 179 1.4× 26 394
Olivier Catalani Switzerland 11 116 0.7× 165 1.0× 198 1.3× 151 1.1× 76 0.6× 17 457
Jacob Haaber Denmark 8 124 0.7× 87 0.5× 192 1.2× 64 0.5× 105 0.8× 13 336
Lixia Pei United States 10 224 1.3× 180 1.1× 312 2.0× 144 1.1× 176 1.4× 27 476
Javier Pérez‐Calvo Spain 9 84 0.5× 107 0.6× 169 1.1× 85 0.6× 140 1.1× 16 398
Nadine Juge‐Morineau France 12 250 1.5× 227 1.3× 266 1.7× 149 1.1× 162 1.3× 18 553
Bernhard J. Woermann Germany 11 132 0.8× 337 2.0× 88 0.6× 220 1.6× 179 1.4× 22 482
Vaishalee P. Kenkre United States 13 258 1.5× 78 0.5× 260 1.7× 208 1.6× 73 0.6× 37 456
Marinus van Oers Netherlands 9 137 0.8× 130 0.8× 100 0.6× 183 1.4× 104 0.8× 17 325
Jerry Ping United States 9 249 1.4× 44 0.3× 134 0.9× 276 2.1× 73 0.6× 15 399

Countries citing papers authored by Stéphanie Guidez

Since Specialization
Citations

This map shows the geographic impact of Stéphanie Guidez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Guidez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Guidez more than expected).

Fields of papers citing papers by Stéphanie Guidez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Guidez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Guidez. The network helps show where Stéphanie Guidez may publish in the future.

Co-authorship network of co-authors of Stéphanie Guidez

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Guidez. A scholar is included among the top collaborators of Stéphanie Guidez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Guidez. Stéphanie Guidez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aymard, M., Morgane Cheminant, Roch Houot, et al.. (2025). Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group. Blood Advances. 10(1). 75–82.
2.
Durot, Éric, Damien Roos‐Weil, Adrien Chauchet, et al.. (2024). High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia. Blood. 143(26). 2804–2807. 3 indexed citations
3.
Aymard, M., Morgane Cheminant, Roch Houot, et al.. (2024). Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group. Blood. 144(Supplement 1). 239–239.
4.
Matasar, Matthew J., Burhan Turgut, Benoît Tessoulin, et al.. (2024). Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).. Journal of Clinical Oncology. 42(16_suppl). TPS7086–TPS7086. 6 indexed citations
5.
Tabaa, Yassine Al, C. Baillet, Emmanuel Bachy, et al.. (2023). Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Advances. 7(14). 3735–3738. 1 indexed citations
6.
Tessoulin, Benoît, Stéphanie Guidez, Nickolas A. Sophos, et al.. (2023). PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3). HemaSphere. 7(S3). e06798be–e06798be. 3 indexed citations
7.
Guidez, Stéphanie, et al.. (2021). Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article. Cancers. 13(20). 5210–5210. 6 indexed citations
8.
Tabaa, Yassine Al, Olivier Casasnovas, C. Baillet, et al.. (2021). PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP. Hematological Oncology. 39(S2). 2 indexed citations
9.
Lévy, Anthony, et al.. (2020). The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma. Frontiers in Oncology. 10. 676–676. 4 indexed citations
10.
Défossez, Gautier, Stéphanie Guidez, Camille Laurent, et al.. (2020). R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry study. Annals of Hematology. 99(7). 1605–1613.
11.
Herbaux, Charles, Olivier Casasnovas, Pierre Feugier, et al.. (2020). Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.. Journal of Clinical Oncology. 38(15_suppl). 8053–8053. 13 indexed citations
12.
Tomowiak, Cécile, et al.. (2019). Maladie de Waldenström. La Presse Médicale. 48(7-8). 832–841. 1 indexed citations
13.
Guidez, Stéphanie, Cécile Tomowiak, Brigitte Dreyfus, et al.. (2018). Oral CHOP-like Chemotherapy in Elderly Patients with High-Grade Non Hodgkin B Cell Lymphoma. Blood. 132(Supplement 1). 4231–4231. 1 indexed citations
14.
Poulain, Stéphanie, Christophe Roumier, Elisabeth Bertrand, et al.. (2017). TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clinical Cancer Research. 23(20). 6325–6335. 62 indexed citations
15.
Evans, Neil D., Bertrand Arnulf, Hervé Avet‐Loiseau, et al.. (2017). Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. Frontiers in Physiology. 8. 149–149. 15 indexed citations
16.
Fouquet, Guillemette, Margaret Macro, O. Decaux, et al.. (2015). Le pomalidomide dans le myélome multiple. La Revue de Médecine Interne. 36(9). 613–618. 1 indexed citations
17.
Boyle, Eileen M., Guillemette Fouquet, Salomon Manier, et al.. (2014). Myélome, IMiD et thrombose. 20(1). 15–22. 1 indexed citations
18.
Fouquet, Guillemette, Claire Bories, Stéphanie Guidez, et al.. (2014). Pomalidomide for multiple myeloma. Expert Review of Hematology. 7(6). 719–731. 22 indexed citations
19.
Fouquet, Guillemette, Stéphanie Guidez, Charles Herbaux, Hélène Demarquette, & Xavier Leleu. (2013). Myélome multiple indolent. La Revue de Médecine Interne. 35(4). 243–249. 1 indexed citations
20.
Herbaux, Charles, Catherine Badens, Stéphanie Guidez, et al.. (2012). A NewATRXMutation in a Patient With Acquiredα-Thalassemia Myelodysplastic Syndrome. Hemoglobin. 36(6). 581–585. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Τατιάνα Τζένου Breakdown of academic impact, for papers by Olivier Catalani Breakdown of academic impact, for papers by Jacob Haaber Breakdown of academic impact, for papers by Lixia Pei Breakdown of academic impact, for papers by Javier Pérez‐Calvo Breakdown of academic impact, for papers by Nadine Juge‐Morineau Breakdown of academic impact, for papers by Bernhard J. Woermann Breakdown of academic impact, for papers by Vaishalee P. Kenkre Breakdown of academic impact, for papers by Marinus van Oers Breakdown of academic impact, for papers by Jerry Ping
Rankless by CCL
2026